Transaction Description
Gemstone acted as financial advisor in ExpreS2ion Biotech’s IPO. The IPO was subscribed at approximately 19.2 MSEK including subscription commitments, corresponding to a subscription rate of approximately 107 percent. Hence the issued guarantee commitments were not activated. Through the IPO, 3,050,000 shares were issued. ExpreS2ion has therefore raised approximately 18 MSEK before emission costs of approximately 1.4 MSEK
Contact Person
Company Description
ExpreS2ion Biotechnologies has created a platform technology to enable the cost-effective and safe production of complex proteins, which are the active ingredient in new vaccines and thus also an important basis in diagnostics, research and development of these new vaccines. Since its inception in 2010, the company has worked with research institutions and pharmaceutical companies and, using its patented ExpreS2 -platform, it has produced over 250 different proteins with an efficiency and success rate, which exceeds competing technologies.
